



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Richard G. Olsen, et al.)
Serial No. 09/125,841) Examiner Ronald B. Schwadron, Ph.D.
Filed: January 19, 1999) Group Art Unit 1644
For: CELLULAR IMMUNOTHERAPY)

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

AMENDMENT AND RESPONSE

Sir:

This paper is filed responsive to the Office action mailed December 10, 2001 (Paper No. 18). The amendments to the claims are submitted herewith as a Clean Set of Amended Claims. A Marked-Up Set of Amended Claims detailing the amendments made also is submitted herewith. In particular, claims 29-35 have been amended and claims 1-28 and 36-41 have been cancelled.

The amendments to the specification are submitted herewith as a Clean Specification. A Marked-Specification detailing the amendments made also is submitted herewith. In particular, page 1 has been amended to claim priority to parent applications. Page 10 also has been amended to remove several typographical errors.

Finally, a new Abstract is submitted, as requested by the Examiner.

A request for extension of time also is enclosed along with an additional fee due to the presentation of additional independent claims.

No new matter has been added by virtue of these amendments.

06/18/2002 HGBREH1 00000020 09125841

02 FC:202

126.00 0P

REMARKS

Reconsideration of the above-identified application respectfully is requested. Claims 1-28 and 36-41 are cancelled, as being drawn to non-elected inventions. Elected claims 29-35 have been amended to include the limitations of the independent claims 22-28, respectively, from which claims 29-35 depended. Entry of the amendments to claims 29-35 respectfully is requested.

Claims 29-35 were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite in that they depend on non-elected claims 22-28. Applicants respectfully traverse the rejection on the basis of claim indefiniteness and grounds therefor. Claims 29-35 have been amended so that they do not depend on non-elected claims.